Back To TOP

Find Patient Assistance Patient Assistance Programs

We offer several options to help cover the cost of ACTEMRA™ (tocilizumab) for your patients who are uninsured, have been denied covered by their health plans, have concerns about co-pays or are worried about out-of-pocket (OOP) expenses.

 

 

 

ACTEMRA Copay card

Genentech offers the ACTEMRA Copay card to help qualified patients with the out-of-pocket costs associated with their prescription.

 

 

 

 

 

Referrals to Co-pay Assistance Foundations

If privately or publicly insured patients have difficulty paying their ACTEMRA co-pay, co-insurance or other expenses, Genentech Rheumatology Access Solutions can refer them to a co-pay assistance foundation* supporting their disease state.

 

 

 

 

 

 

 

The Genentech® Access to Care Foundation (GATCF)

GATCF was established to help patients with unmet medical needs who are uninsured or rendered uninsured by payer denial and who meet specific financial and medical criteria to receive  ACTEMRA free of charge. Learn more

 

* Genentech does not influence or control the operations of these co-pay assistance foundations, but Genentech Rheumatology Access Solutions can assist patients in navigating the process of seeking co-pay assistance by making an appropriate referral based on a patient’s diagnosis and by assisting with the application process. We cannot guarantee co-pay assistance once a patient has been referred by Genentech Rheumatology Access Solutions. The foundations to which we refer patients each have their own criteria for patient eligibility, including financial eligibility.
   
   
   
   

 

 

FAQs

 
Q:

When should I refer my patient to Genentech Rheumatology Access Solutions for ACTEMRA for help?

 
A: 

At any point after you have prescribed ACTEMRA® (tocilizumab), you can refer your patient to Genentech Rheumatology Access Solutions. Learn more in See How We Can Help.

 

 

Q:

 

Can Genentech Rheumatology Access Solutions assist with co-pay issues?

 
A: 

Yes. We can help with co-pay issues in two ways, for both privately and publicly insured patients. Learn more in Find Patient Assistance.

 

 

Q:

 

Is there assistance for uninsured patients who have been prescribed ACTEMRA?

 
A: 

Yes. The Genentech® Access to Care Foundation provides help for qualified patients. These include patients who are uninsured or whose health plans have denied payment for ACTEMRA. They must meet certain financial and medical requirements. Learn more in Help For Uninsured Patients.

 

 

Learn More About
ACTEMRA
  • LEARN about treatment with ACTEMRA
  • NOW APPROVED: ACTEMRA for DMARD-Inadequate Response Patients
  • LEARN HOW the ACTEMRA Copay Card can help with the out-of-pocket costs for ACTEMRA
  • Form Statement of Medical Necessity
  • Form Patient Authorization and Notice of Release of Information (Current Version)

Actemra Indications and Important Safety Information

INDICATIONS

ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections.

If a serious infection develops, interrupt ACTEMRA until the infection is controlled.

ACTEMRA should not be administered to patients with known hypersensitivity to ACTEMRA. Hypersensitivity reactions, including anaphylaxis and dealth have occured.

  • If anaphylaxis or other clinically significant hypersensitivity reaction occurs, administration of ACTEMRA should be stopped immediately and ACTEMRA should be permanently discontinued.

Other serious or potentially life-threatening adverse reactions that have been reported in clinical trials with ACTEMRA include gastrointestinal perforations and hypersensitivity reactions.

Other potential risks of ACTEMRA include demyelinating disorders, malignancies and changes to certain lab parameters.

Common adverse reactions in RA studies included upper respiratory infection, nasopharyngitis, headache, hypertension, and increased ALT.

Common adverse reactions in SJIA studies included upper respiratory tract infection, headache, nasopharyngitis and diarrhea.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see full Prescribing Information, including Boxed Warning for additional important safety information.